Onchilles Pharma Advances NEU-002 Program for Systemic Cancer Treatment
Onchilles Pharma has presented new preclinical data from its NEU-002 program at the AACR Annual Meeting 2026. The program focuses on extending the ELANE pathway into systemic delivery, targeting solid tumors with a cancer-selective mechanism that spares immune cells while activating anti-tumor immunity. Preclinical models demonstrated anti-tumor activity following intravenous and intraperitoneal administration, with two lead candidates advancing toward final development candidate selection. The NEU-002 program aims to protect elastase activity against circulating serine protease inhibitors, supporting its potential as a systemic approach for solid tumors. 
